[go: up one dir, main page]

SG11201908465QA - Substituted indoline derivatives as dengue viral replication inhibitors - Google Patents

Substituted indoline derivatives as dengue viral replication inhibitors

Info

Publication number
SG11201908465QA
SG11201908465QA SG11201908465QA SG11201908465QA SG 11201908465Q A SG11201908465Q A SG 11201908465QA SG 11201908465Q A SG11201908465Q A SG 11201908465QA SG 11201908465Q A SG11201908465Q A SG 11201908465QA
Authority
SG
Singapore
Prior art keywords
leuven
international
dengue viral
compounds
janssen
Prior art date
Application number
Other languages
English (en)
Inventor
Dorothée Alice Marie-Eve Bardiot
Bart Rudolf Romanie Kesteleyn
Jean-François Bonfanti
Pierre Jean-Marie Bernard Raboisson
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of SG11201908465QA publication Critical patent/SG11201908465QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201908465Q 2017-03-31 2018-03-29 Substituted indoline derivatives as dengue viral replication inhibitors SG11201908465QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164045 2017-03-31
PCT/EP2018/058077 WO2018178238A1 (fr) 2017-03-31 2018-03-29 Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue

Publications (1)

Publication Number Publication Date
SG11201908465QA true SG11201908465QA (en) 2019-10-30

Family

ID=58464339

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908465Q SG11201908465QA (en) 2017-03-31 2018-03-29 Substituted indoline derivatives as dengue viral replication inhibitors

Country Status (31)

Country Link
US (1) US11179368B2 (fr)
EP (1) EP3601225B1 (fr)
JP (1) JP7038733B2 (fr)
KR (1) KR102556222B1 (fr)
CN (1) CN110612284B (fr)
AR (1) AR111315A1 (fr)
AU (1) AU2018246299A1 (fr)
BR (1) BR112019019928A2 (fr)
CA (1) CA3055260A1 (fr)
CL (1) CL2019002744A1 (fr)
CO (1) CO2019010292A2 (fr)
CR (1) CR20190447A (fr)
DK (1) DK3601225T3 (fr)
EA (1) EA201992334A1 (fr)
EC (1) ECSP19070413A (fr)
ES (1) ES2887673T3 (fr)
HR (1) HRP20211102T1 (fr)
HU (1) HUE055576T2 (fr)
IL (1) IL269657A (fr)
JO (1) JOP20180026A1 (fr)
LT (1) LT3601225T (fr)
MA (1) MA48987A (fr)
MX (1) MX2019011608A (fr)
NI (1) NI201900098A (fr)
PE (1) PE20191652A1 (fr)
PH (1) PH12019502095A1 (fr)
SG (1) SG11201908465QA (fr)
SI (1) SI3601225T1 (fr)
TW (1) TW201900610A (fr)
UY (1) UY37646A (fr)
WO (1) WO2018178238A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102359743B1 (ko) 2016-03-31 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌 유도체
KR102359735B1 (ko) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
SG11201808237UA (en) 2016-04-01 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue
CN109485596A (zh) * 2018-12-19 2019-03-19 山东理工职业学院 一种含吲哚啉的登革病毒抑制剂的制备方法
CN119306651B (zh) * 2024-10-11 2025-12-05 山东大学 一种吲哚3-酰胺类衍生物及其制备方法与应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021559A1 (fr) 1997-10-27 1999-05-06 Eli Lilly And Company PROMEDICAMENTS D'ESTER DE MORPHOLINO-N-ETHYLE D'INHIBITEURS INDOLIQUES DE sPLA¿2?
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
RU2007130896A (ru) 2005-01-14 2009-02-20 Дженелэбс Текнолоджиз, Инк. (Us) Индольные производные для лечения вирусных инфекций
CN101304762A (zh) 2005-02-09 2008-11-12 米珍尼克斯公司 治疗或预防黄病毒科感染的组合物和方法
US9029376B2 (en) 2008-06-03 2015-05-12 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
ES2612731T3 (es) 2008-08-19 2017-05-18 Janssen Pharmaceutica Nv Antagonistas de receptores al frío de mentol
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
EP2393359A4 (fr) 2009-02-09 2012-10-03 Enanta Pharm Inc Dérivés du dibenzimidazole liés
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
EA201290575A1 (ru) 2010-01-15 2013-01-30 Джилид Сайэнс, Инк. Ингибиторы вирусов flaviviridae
WO2011120025A1 (fr) 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines utilisés en tant qu'inhibiteurs de kinase
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびb型肝炎の処置のための医薬品としてのその使用
UY40230A (es) 2014-01-31 2023-08-15 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden
NO2721243T3 (fr) 2014-10-01 2018-10-20
ME03344B (fr) 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc Indoles monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA40768B1 (fr) 2014-10-01 2019-03-29 Janssen Pharmaceuticals Inc Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6864001B2 (ja) 2015-11-03 2021-04-21 ゾエティス・サービシーズ・エルエルシー ゾル−ゲルポリマー組成物及びそれらの使用
KR102359743B1 (ko) 2016-03-31 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌 유도체
KR102359735B1 (ko) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
SG11201808237UA (en) 2016-04-01 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
DK3436030T3 (da) 2016-04-01 2022-11-21 Kite Pharma Inc Kimæriske receptorer og fremgangsmåder til anvendelse deraf
CN109069512B (zh) 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
CA3015934A1 (fr) 2016-04-01 2017-10-05 Basf Se Composes bicycliques
AU2017240801A1 (en) 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
KR102556222B1 (ko) 2023-07-14
CN110612284A (zh) 2019-12-24
CO2019010292A2 (es) 2019-10-09
JOP20180026A1 (ar) 2019-01-30
UY37646A (es) 2018-09-28
JP7038733B2 (ja) 2022-03-18
BR112019019928A2 (pt) 2020-04-22
WO2018178238A1 (fr) 2018-10-04
HRP20211102T1 (hr) 2021-10-29
EA201992334A1 (ru) 2020-02-20
CA3055260A1 (fr) 2018-10-04
AR111315A1 (es) 2019-06-26
DK3601225T3 (da) 2021-08-16
MX2019011608A (es) 2019-11-08
AU2018246299A1 (en) 2019-09-19
PE20191652A1 (es) 2019-11-07
US20200054606A1 (en) 2020-02-20
CN110612284B (zh) 2023-10-31
TW201900610A (zh) 2019-01-01
US11179368B2 (en) 2021-11-23
EP3601225B1 (fr) 2021-06-02
CR20190447A (es) 2019-11-13
ECSP19070413A (es) 2019-10-31
MA48987A (fr) 2020-02-05
HUE055576T2 (hu) 2021-12-28
KR20190135496A (ko) 2019-12-06
SI3601225T1 (sl) 2021-09-30
IL269657A (en) 2019-11-28
JP2020512374A (ja) 2020-04-23
ES2887673T3 (es) 2021-12-27
EP3601225A1 (fr) 2020-02-05
NI201900098A (es) 2020-03-11
PH12019502095A1 (en) 2020-03-09
LT3601225T (lt) 2021-08-10
CL2019002744A1 (es) 2019-12-27

Similar Documents

Publication Publication Date Title
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof